Search in:

Advanced search

ClinicoEconomics and Outcomes Research Volume 9, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

Luca Degli Esposti1 CliCon S.r.l. – Health, Economics & Outcomes Research, Ravenna

Ennio Giulio Favalli2 Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan

Diego Sangiorgi1 CliCon S.r.l. – Health, Economics & Outcomes Research, Ravenna

Roberta Di Turi3 Local Pharmaceutical and Supplementary Assistance Unit, Roma Local Health Authority D, Rome

Giuseppina Farina4 Internal Management Control Unit – Pharmaceutical Spending Control Sector, Caserta Local Health Authority, Caserta

Marco Gambera5 Local Pharmaceutical Service, Bergamo Local Health Authority, Bergamo

Roberto Ravasio6 Health Publishing & Services Srl, Milan, ItalyCorrespondence[email protected]

show all

Pages 9-17 | Published online: 21 Dec 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GibofskyAEpidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsisAm J Manag Care2014207 supplS128S13525180621
PubMed Web of Science ®Google Scholar
GibofskyAOverview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritisAm J Manag Care20121813 supplS295S30223327517
PubMedGoogle Scholar
SinghJAFurstDEBharatA2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res2012645625639
PubMed Web of Science ®Google Scholar
KvienTKEpidemiology and burden of illness of rheumatoid arthritisPharmacoeconomics200422Suppl 1112
PubMed Web of Science ®Google Scholar
De MariaANRelative risk of cardiovascular events in patients with rheumatoid arthritisAm J Cardiol2002896A33D38D
Web of Science ®Google Scholar
LubeckDPPatient-reported outcomes and their role in the assessment of rheumatoid arthritisPharmacoeconomics200422Suppl 1273815157002
PubMed Web of Science ®Google Scholar
CerraCRavasioRPolcaroFIl costo dell’Artrite Reumatoide: l’esperienza dell’ASL della Provincia di PaviaGiornale Italiano di Health Technol Assess200923111117
Google Scholar
ShichikawaKInoueKHirotaSChanges in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965–1996Ann Rheum Dis19995875175610577961
PubMed Web of Science ®Google Scholar
CimminoMAParisiAMoggianaGPrevalence of rheumatoid arthritis in Italy: the Chiavari studyAnn Rheum Dis1998573153189741317
PubMed Web of Science ®Google Scholar
SmolenJSLandeweRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis20106996497520444750
PubMed Web of Science ®Google Scholar
NellVPMacholdKPEbrelGBenefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology20044390691415113999
PubMed Web of Science ®Google Scholar
EmeryPBreedveldFCDougadosMEarly referral recommendation for newly diagnosed rheumatoid arthritis: evidence-based development of a clinical guideAnn Rheum Dis20026129029711874828
PubMed Web of Science ®Google Scholar
KuekAHazlemanBLÖstorAJKImmune mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgrad Med J20078325126017403952
PubMed Web of Science ®Google Scholar
LeeDMWeinblattMERheumatoid arthritisLancet200135890391111567728
PubMed Web of Science ®Google Scholar
CaporaliRContiFAliverniniSRecommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. EfficacyClin Exp Rheumatol201129Suppl 66S7S1421906423
PubMed Web of Science ®Google Scholar
MarkensonJAGibofskyAPalmerWRPersistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJ Rheumatol20113871273128121572150
PubMed Web of Science ®Google Scholar
CramerJASilvermanSPersistence with bisphosphonate treatment for osteoporosis: finding the root of the problemAm J Med20061194 Suppl 1S12S17
PubMed Web of Science ®Google Scholar
World Health OrganizationAdherence to Long-Term Therapies: Evidence for ActionGenevaWorld Health Organization2003
Google Scholar
HughesDCowellWKonczTCramerJInternational Society for Pharmacoeconomics and Outcomes Research Economics of Medication Compliance Working GroupMethods for integrating medication compliance and persistence in pharmacoeconomic evaluationsValue Health200710649850917970932
PubMed Web of Science ®Google Scholar
CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
PubMed Web of Science ®Google Scholar
BonafedeMMGandraSRFoxKMWilsonKLTumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationJ Med Econ201215463564322332705
PubMedGoogle Scholar
DarkowTChastekBRosenblattLTrivediDHebdenTHenkHLiuFDose Escalation among rheumatoid arthritis patients treated with infliximab or abatacept: comparison in claims dataArthritis Rheum20116310122121305507
PubMed Web of Science ®Google Scholar
IannoneFGremeseEAtzeniFLongterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictorsJ Rheumatol20123961179118422467933
PubMed Web of Science ®Google Scholar
MarchesoniAZaccaraEGorlaRTNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn NY Acad Sci20091173183784619758236
PubMed Web of Science ®Google Scholar
FavalliEGBiggioggeroMPregnolatoFBeccioliniAPenattiAEMarchesoniAMeroniPLThe 12-year retention rate of the first-line TNF-inhibitor in the treatment of rheumatoid arthritis: real-life data from a local registryArthritis Care Res (Hoboken) Epub20151110
Web of Science ®Google Scholar
FavalliEGMarchesoniAColomboGLPattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in ItalyClin Exp Rheumatol200826455118328146
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date